²¹¹At-BC8-B10 is a radioimmunoconjugate containing the murine IgG1 anti-CD45 monoclonal antibody BC8 where the lysine side groups have been conjugated with decaborate (B10) and labeled with Astatine-211. The drug is developed at the Fred Hutchinson Cancer Center, Seattle WA, USA, with the support of the NCI, in patients with high-risk acute leukemia or myelodysplastic syndrome
Two clinical studies are presently under way with completion expected respectively in 2024 and 2025.

Target/Mechanism: CD45

Carrier/Ligand: BC8

Radiation Type: Alpha particle (α)